Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30437401 | 0.89 | KMT2A (0.50) | KMT2AMEN1PARP10ALDH1A1LMNA | |
| SCHEMBL143772 | 0.83 | MEN1 (0.61) | KMT2AMEN1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL28453082 | 0.83 | KMT2A (0.45) | KMT2AMEN1ALDH1A1LMNAMAPK1 | |
| SCHEMBL147245 | 0.81 | KMT2A (0.44) | KMT2AMEN1PARP10ALDH1A1LMNA | |
| SCHEMBL28453084 | 0.81 | ALDH1A1 (0.45) | KMT2AMEN1ALDH1A1LMNAMAPK1 | |
| SCHEMBL1934595 | 0.81 | KMT2A (0.44) | KMT2AMEN1PARP10ALDH1A1LMNA | |
| SCHEMBL5709288 | 0.81 | TPSAB1 (0.51) | KMT2AMEN1PARP10ALDH1A1PRSS1 | |
| SCHEMBL13429420 | 0.80 | ALDH1A1 (0.40) | KMT2AMEN1PARP10ALDH1A1LMNA | |
| SCHEMBL17080518 | 0.79 | CYP3A4 (0.54) | KMT2AMEN1PARP10 | |
| SCHEMBL21385042 | 0.79 | KMT2A (0.42) | KMT2AMEN1PARP10ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111542345-B | Chlorotoxin agent and use thereof | 卫材公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240374748-A1 | TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-11-14 | — | — | US | disclosed |
| US-20240307561-A1 | RADIOLABELED PARP INHIBITOR CONJUGATES FOR CANCER TREATMENT | DUKE UNIVERSITY (US) | 2024-09-19 | — | — | US | disclosed |
| EP-3383920-B1 | TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN | UNIV CALIFORNIA (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11826399-B2 | Chlorotoxin agents and uses thereof | EISAI INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11739069-B2 | Modulators of resistant androgen receptor | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-08-29 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2007117467-A2 | USE OF TM-601 FOR THE DIAGNOSIS AND TREATMENT OF TUMORS | TRANSMOLECULAR, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070237714-A1 | Diagnosis and treatment of tumors | MORPHOTEK, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070231333-A1 | ANTI-5T4 ANTIBODIES AND USES THEREOF | WYETH (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2007106744-A2 | ANTI-5T4 ANTIBODIES AND USES THEREOF | WYETH (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070160577-A1 | Interleukin-11 compositions and methods of use | WYETH (US) | 2007-07-12 | — | — | US | disclosed |
| WO-2007067602-A1 | INTERLEUKIN-11 COMPOSITIONS AND METHODS OF USE | WYETH (US) | 2007-06-14 | — | — | WO | disclosed |
| EP-1786469-A2 | HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4 ANTIBODY / CALICHEAMICIN CONJUGATES | Wyeth a Corporation of the State of Delaware (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060088522-A1 | Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugates | WYETH (US) | 2006-04-27 | — | — | US | disclosed |
| WO-2006031653-A2 | HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4 ANTIBODY / CALICHEAMICIN CONJUGATES | WYETH (US) | 2006-03-23 | — | — | WO | disclosed |
| EP-0317956-A2 | Anti-tumor prodrugs | Bristol-Myers Squibb Company (US) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | KMT2A 2431/4885MEN1 367/4885PARP10 2872/4885 |
| US-11826399-B2 | Chlorotoxin agents and uses thereof | NRP1, LCP1, CLSPN | KMT2A 1894/4885MEN1 2123/4885PARP10 658/4885 |
| US-20240307561-A1 | RADIOLABELED PARP INHIBITOR CONJUGATES FOR CANCER TREATMENT | PARP1, PARP2, PARP3 | KMT2A 896/4885MEN1 761/4885PARP10 13/4885 |
| US-11739069-B2 | Modulators of resistant androgen receptor | AR, NR5A1, ESRRA | KMT2A 1594/4885MEN1 4337/4885PARP10 1146/4885 |
| US-20060088522-A1 | Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugates | FUT4, ABCC4, SLC26A4 | KMT2A 1616/4885MEN1 1043/4885PARP10 4442/4885 |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | KMT2A 2431/4885MEN1 367/4885PARP10 2872/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | KMT2A 2431/4885MEN1 367/4885PARP10 2872/4885 |
| US-20070231333-A1 | ANTI-5T4 ANTIBODIES AND USES THEREOF | SLC26A4, ABCC4, SLC5A7 | KMT2A 595/4885MEN1 432/4885PARP10 3673/4885 |
| US-20240374748-A1 | TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN | ALPP, HLA-A, ALPI | KMT2A 1997/4885MEN1 1914/4885PARP10 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.